LISTING OF CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-60 (Canceled)

61. (previously presented) A method of ameliorating hepatic steatosis in an animal comprising administering to said animal a therapeutically effective amount of an antisense compound that specifically hybridizes with a nucleic acid molecule encoding apolipoprotein C-III (SEQ ID NO: 4) and inhibits the expression of apolipoprotein C-III so that hepatic steatosis is ameliorated.

62. (previously presented) The method of Claim 61, wherein the hepatic steatosis is steatohepatitis.

63. (previously presented)The method of Claim 61, wherein the hepatic steatosis is non-alcoholic steatohepatitis.

~~66.~~ 64. (currently amended) The method of Claim 61, wherein said antisense compound comprises an oligonucleotide.

~~67~~ 65. (currently amended) The method of Claim ~~66~~ 64, wherein said oligonucleotide comprises a single-stranded nucleotide.

~~68.~~ 66. (currently amended) The method of Claim ~~67~~ 65, wherein said oligonucleotide comprises at least one modified internucleoside linkage, sugar moiety, or nucleobase.

~~69.~~ 67. (currently amended) The method of Claim ~~68~~ 66, wherein said modified internucleoside linkage is a phosphorothioate linkage.

~~70.~~ 68. (currently amended) The method of Claim ~~68~~ 66, wherein said modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

~~71.~~ 69. (currently amended) The method of Claim ~~68~~ 66, wherein said modified nucleobase is a 5-methylcytosine.

~~72.~~ 70. (currently amended) A method of lowering liver tissue triglyceride levels in an animal comprising administering to said animal a therapeutically effective amount of an antisense compound that specifically hybridizes with a nucleic acid molecule encoding apolipoprotein C-

III (SEQ ID NO: 4), wherein said antisense compound inhibits the expression of apolipoprotein C-III and thereby lowers liver tissue triglyceride levels.

~~73.~~ 71. (currently amended) The method of Claim ~~72~~ 70, wherein said antisense compound comprises an oligonucleotide.

~~74.~~ 72. (currently amended) The method of Claim ~~73~~ 71, wherein said oligonucleotide comprises a single-stranded nucleotide.

~~75.~~ 73. (currently amended) The method of Claim ~~74~~ 72, wherein said oligonucleotide comprises at least one modified internucleoside linkage, sugar moiety, or nucleobase.

~~76.~~ 74. (currently amended) The method of Claim ~~75~~ 73, wherein said modified internucleoside linkage is a phosphorothioate linkage.

~~77.~~ 75. (currently amended) The method of Claim ~~75~~ 73, wherein said modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

~~78.~~ 76. (currently amended) The method of Claim ~~75~~ 73, wherein said modified nucleobase is a 5-methylcytosine.

~~79.~~ 77. (currently amended) A method of reducing adipose tissue in an animal comprising administering to said animal a therapeutically effective amount of an antisense compound that specifically hybridizes with a nucleic acid molecule encoding apolipoprotein C-III (SEQ ID NO: 4) wherein said antisense compound inhibits the expression of apolipoprotein C-III and thereby reduces adipose tissue.

~~80.~~ 78. (currently amended) The method of Claim ~~79~~ 77, wherein said antisense compound comprises an oligonucleotide.

~~81.~~ 79. (currently amended) The method of Claim ~~80~~ 78, wherein said oligonucleotide comprises a single-stranded nucleotide.

~~82.~~ 80. (currently amended) The method of Claim ~~81~~ 79, wherein said oligonucleotide comprises at least one modified internucleoside linkage, sugar moiety, or nucleobase.

~~83.~~ 81. (currently amended) The method of Claim ~~82~~ 80, wherein said modified internucleoside linkage is a phosphorothioate linkage.

~~84.~~ 82. (currently amended) The method of Claim ~~82~~ 80, wherein said modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

~~85.~~ 83. (currently amended) The method of Claim ~~82~~ 80, wherein said modified nucleobase is a 5-methylcytosine.